Vericel Corporation $VCEL Shares Purchased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB increased its holdings in Vericel Corporation (NASDAQ:VCEL) by 101.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 117,000 shares of the biotechnology company’s stock after acquiring an additional 59,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Vericel were worth $3,682,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VCEL. William Blair Investment Management LLC grew its holdings in shares of Vericel by 90.3% during the 3rd quarter. William Blair Investment Management LLC now owns 2,210,929 shares of the biotechnology company’s stock worth $69,578,000 after purchasing an additional 1,048,864 shares during the period. Geode Capital Management LLC raised its holdings in Vericel by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,240,389 shares of the biotechnology company’s stock valued at $52,786,000 after buying an additional 38,799 shares during the period. Champlain Investment Partners LLC raised its holdings in Vericel by 62.5% in the 2nd quarter. Champlain Investment Partners LLC now owns 997,291 shares of the biotechnology company’s stock valued at $42,435,000 after buying an additional 383,498 shares during the period. New York State Common Retirement Fund lifted its position in Vericel by 3.3% in the second quarter. New York State Common Retirement Fund now owns 890,509 shares of the biotechnology company’s stock valued at $37,891,000 after buying an additional 28,178 shares during the last quarter. Finally, TimesSquare Capital Management LLC boosted its stake in Vericel by 12.6% during the third quarter. TimesSquare Capital Management LLC now owns 836,861 shares of the biotechnology company’s stock worth $26,336,000 after buying an additional 93,472 shares during the period.

Vericel Trading Down 0.9%

Vericel stock opened at $33.71 on Friday. Vericel Corporation has a twelve month low of $29.24 and a twelve month high of $50.36. The stock’s fifty day simple moving average is $36.80 and its 200-day simple moving average is $36.06. The firm has a market capitalization of $1.71 billion, a P/E ratio of 108.74 and a beta of 1.22.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, February 26th. The biotechnology company reported $0.45 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.45. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The firm had revenue of $92.92 million during the quarter, compared to analyst estimates of $92.66 million. During the same period last year, the business posted $0.38 earnings per share. Vericel’s revenue was up 23.3% compared to the same quarter last year. Sell-side analysts predict that Vericel Corporation will post 0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on VCEL shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Zacks Research cut shares of Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. HC Wainwright lifted their target price on shares of Vericel from $60.00 to $64.00 and gave the company a “buy” rating in a report on Friday, February 27th. Wall Street Zen lowered Vericel from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Truist Financial lowered their price target on Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.